New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on... | May 25, 2023
Source: marketscreener.com
Total Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Total Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Total Trial Today - Breaking & Trending Today
PHARNEXT: After 6 years of total trial time, data from the open-label PLEO-CMT-FU trial are consistent with a long-term benefit of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on
Source: finanznachrichten.de